Celgene's Phase 3 Study Of REMARC Likely To Be Successful, Says Jefferies
June 28, 2016 at 17:21 PM EDT
Success in Celgene Corporation (NASDAQ: CELG)’s Phase III Revlimid Study for lymphoma isn't a sure thing. However, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.